Literature DB >> 9933343

Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia.

M Piert1, H Machulla, G Becker, A Stahlschmidt, M Patt, P Aldinger, P D Dissmann, H Fischer, R Bares, H D Becker, W Lauchart.   

Abstract

Fluorine-18 labelled fluoromisonidazole ([18F]FMISO) has been shown to accumulate in hypoxic tissue in inverse proportion to tissue oxygenation. In order to evaluate the potential of [18F]FMISO as a possible positron emission tomography (PET) tracer for imaging of liver tissue hypoxia, we measured the [18F]FMISO uptake in 13 domestic pigs using dynamic PET scanning. Hypoxia was induced by segmental arterial hepatic occlusion. During the experimental procedure the fractional concentration of inspired oxygen (FiO2) was set to 0.67 in group A (n=6) and to 0.21 in group B (n=7) animals. Before and after arterial occlusion, the partial pressure of O2 in tissue (TPO2) and the arterial blood flow were determined in normal flow and flow-impaired liver segments. Standardised uptake values [SUV=kBq tissue (in g) / body weight (in kg) x injected dose (in kBq)] for [18F]FMISO were calculated from PET images obtained 3 hours after injection of about 10 MBq/kg body weight [18F]FMISO. Immediately before PET scanning, the mean arterial blood flow was significantly decreased in arterially occluded segments [group A: 0. 41 (0.32-0.52); group B: 0.24 (0.16-0.33) ml min-1 g-1] compared with normal flow segments [group A: 1.05 (0.76-1.46); group B: 1.14 (0.83-1.57) ml min-1 g-1; geometric mean (95% confidence limits); P<0.001 for both groups]. After PET scanning, the TPO2 of occluded segments (group A: 5.1 (4.1-6.4); group B: 3.5 (2.6-4.9) mmHg] was significantly decreased compared with normal flow segments [group A: 26.4 (21.2-33.0); group B: 18.2 (13.3-25.1) mmHg; P<0.001 for both groups]. During the 3-h PET scan, the mean [18F]FMISO SUV determined in occluded segments increased significantly to 3.84 (3.12-4.72) in group A and 5.7 (4.71-6.9) in group B, while the SUV remained unchanged in corresponding normal liver tissue [group A: 1.4 (1.14-1. 71); group B: 1.31 (1.09-1.57); P<0.001 for both groups]. Regardless of ventilation conditions, a significant inverse exponential relationship was found between the TPO2 and the [18F]FMISO SUV (r2=0. 88, P<0.001). Our results suggest that because tracer delivery to hypoxic tissues was maintained by the portal circulation, the [18F]FMISO accumulation in the liver was found to be directly related to the severity of tissue hypoxia. Thus, [18F]FMISO PET allows in vivo quantification of pig liver hypoxia using simple SUV analysis as long as tracer delivery is not critically reduced.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933343     DOI: 10.1007/s002590050365

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  13 in total

1.  From anatomical to biological target volumes: the role of PET in radiation treatment planning.

Authors:  D A X Schinagl; J H A M Kaanders; W J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

2.  Standardized uptake value in high uptake area on positron emission tomography with 18F-FRP170 as a hypoxic cell tracer correlates with intratumoral oxygen pressure in glioblastoma.

Authors:  Takaaki Beppu; Kazunori Terasaki; Toshiaki Sasaki; Shunrou Fujiwara; Hideki Matsuura; Kuniaki Ogasawara; Koichiro Sera; Noriyuki Yamada; Noriyuki Uesugi; Tamotsu Sugai; Kohsuke Kudo; Makoto Sasaki; Shigeru Ehara; Ren Iwata; Yoshihiro Takai
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488

3.  FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.

Authors:  Michael Zimny; Bernd Gagel; Ercole DiMartino; Kurt Hamacher; Heinz H Coenen; Martin Westhofen; Michael Eble; Ulrich Buell; Patrick Reinartz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-14       Impact factor: 9.236

4.  Limitations of Fluorine 18 Fluoromisonidazole in Assessing Treatment-induced Tissue Hypoxia after Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Prospective Pilot Study.

Authors:  Rajesh P Shah; Paul F Laeseke; Lewis K Shin; Frederick T Chin; Nishita Kothary; George M Segall
Journal:  Radiol Imaging Cancer       Date:  2022-05

Review 5.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 6.  Tumor hypoxia: a new PET imaging biomarker in clinical oncology.

Authors:  Nagara Tamaki; Kenji Hirata
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

Review 7.  Novel imaging approaches to head and neck cancer.

Authors:  Kenneth A Krohn; Bevan Yeuh
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

8.  (18)F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors.

Authors:  Takuya Toyonaga; Kenji Hirata; Shigeru Yamaguchi; Kanako C Hatanaka; Sayaka Yuzawa; Osamu Manabe; Kentaro Kobayashi; Shiro Watanabe; Tohru Shiga; Shunsuke Terasaka; Hiroyuki Kobayashi; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-03       Impact factor: 9.236

9.  Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).

Authors:  Florian C Maier; Manfred Kneilling; Gerald Reischl; Funda Cay; Daniel Bukala; Andreas Schmid; Martin S Judenhofer; Martin Röcken; Hans-Jürgen Machulla; Bernd J Pichler
Journal:  Radiat Oncol       Date:  2011-11-25       Impact factor: 3.481

10.  Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry.

Authors:  L Dubois; W Landuyt; K Haustermans; P Dupont; G Bormans; P Vermaelen; P Flamen; E Verbeken; L Mortelmans
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.